Mei W Baker1,2, Anne E Atkins2, Suzanne K Cordovado3, Miyono Hendrix3, Marie C Earley3, Philip M Farrell1,4. 1. Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA. 2. Newborn Screening Laboratory, Wisconsin State Laboratory of Hygiene, University of Wisconsin-Madison, Madison, Wisconsin, USA. 3. The Newborn Screening and Molecular Biology Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. 4. Department of Population Health Sciences, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
Abstract
PURPOSE: Many regions have implemented newborn screening (NBS) for cystic fibrosis (CF) using a limited panel of cystic fibrosis transmembrane regulator (CFTR) mutations after immunoreactive trypsinogen (IRT) analysis. We sought to assess the feasibility of further improving the screening using next-generation sequencing (NGS) technology. METHODS: An NGS assay was used to detect 162 CFTR mutations/variants characterized by the CFTR2 project. We used 67 dried blood spots (DBSs) containing 48 distinct CFTR mutations to validate the assay. NGS assay was retrospectively performed on 165 CF screen-positive samples with one CFTR mutation. RESULTS: The NGS assay was successfully performed using DNA isolated from DBSs, and it correctly detected all CFTR mutations in the validation. Among 165 screen-positive infants with one CFTR mutation, no additional disease-causing mutation was identified in 151 samples consistent with normal sweat tests. Five infants had a CF-causing mutation that was not included in this panel, and nine with two CF-causing mutations were identified. CONCLUSION: The NGS assay was 100% concordant with traditional methods. Retrospective analysis results indicate an IRT/NGS screening algorithm would enable high sensitivity, better specificity and positive predictive value (PPV). This study lays the foundation for prospective studies and for introducing NGS in NBS laboratories.
PURPOSE: Many regions have implemented newborn screening (NBS) for cystic fibrosis (CF) using a limited panel of cystic fibrosis transmembrane regulator (CFTR) mutations after immunoreactive trypsinogen (IRT) analysis. We sought to assess the feasibility of further improving the screening using next-generation sequencing (NGS) technology. METHODS: An NGS assay was used to detect 162 CFTR mutations/variants characterized by the CFTR2 project. We used 67 dried blood spots (DBSs) containing 48 distinct CFTR mutations to validate the assay. NGS assay was retrospectively performed on 165 CF screen-positive samples with one CFTR mutation. RESULTS: The NGS assay was successfully performed using DNA isolated from DBSs, and it correctly detected all CFTR mutations in the validation. Among 165 screen-positive infants with one CFTR mutation, no additional disease-causing mutation was identified in 151 samples consistent with normal sweat tests. Five infants had a CF-causing mutation that was not included in this panel, and nine with two CF-causing mutations were identified. CONCLUSION: The NGS assay was 100% concordant with traditional methods. Retrospective analysis results indicate an IRT/NGS screening algorithm would enable high sensitivity, better specificity and positive predictive value (PPV). This study lays the foundation for prospective studies and for introducing NGS in NBS laboratories.
Authors: Carlo Castellani; Luigi Picci; Maurizio Scarpa; Maria Cristina Dechecchi; Luisa Zanolla; Baroukh Maurice Assael; Franco Zacchello Journal: Am J Med Genet A Date: 2005-06-01 Impact factor: 2.802
Authors: Claude Férec; Teresa Casals; Nadia Chuzhanova; Milan Macek; Thierry Bienvenu; Andrea Holubova; Caitriona King; Trudi McDevitt; Carlo Castellani; Philip M Farrell; Molly Sheridan; Sarah-Jane Pantaleo; Ourida Loumi; Taieb Messaoud; Harry Cuppens; Francesca Torricelli; Garry R Cutting; Robert Williamson; Maria Jesus Alonso Ramos; Pier Franco Pignatti; Odile Raguénès; David N Cooper; Marie-Pierre Audrézet; Jian-Min Chen Journal: Eur J Hum Genet Date: 2006-05 Impact factor: 4.246
Authors: R G Gregg; A Simantel; P M Farrell; R Koscik; M R Kosorok; A Laxova; R Laessig; G Hoffman; D Hassemer; E H Mischler; M Splaingard Journal: Pediatrics Date: 1997-06 Impact factor: 7.124
Authors: J Zielenski; T M Fujiwara; D Markiewicz; A J Paradis; A I Anacleto; B Richards; R H Schwartz; K W Klinger; L C Tsui; K Morgan Journal: Am J Hum Genet Date: 1993-03 Impact factor: 11.025
Authors: Anja Kammesheidt; Martin Kharrazi; Steve Graham; Suzanne Young; Michelle Pearl; Charles Dunlop; Steven Keiles Journal: Genet Med Date: 2006-09 Impact factor: 8.822
Authors: H Levy; M Nugent; K Schneck; D Stachiw-Hietpas; A Laxova; O Lakser; M Rock; M K Dahmer; J Biller; S Z Nasr; M Baker; S A McColley; P Simpson; P M Farrell Journal: Clin Genet Date: 2016-01-20 Impact factor: 4.438
Authors: Martina I Lefterova; Peidong Shen; Justin I Odegaard; Eula Fung; Tsoyu Chiang; Gang Peng; Ronald W Davis; Wenyi Wang; Martin Kharrazi; Iris Schrijver; Curt Scharfe Journal: J Mol Diagn Date: 2016-02-01 Impact factor: 5.568
Authors: Stacey Lee; Jennifer L Taylor; Charles Redmond; Andrew G Hadd; Jon A Kemppainen; Brian C Haynes; Scott Shone; Donald B Bailey; Gary J Latham Journal: J Mol Diagn Date: 2019-12-19 Impact factor: 5.568